CB2 modulation of pruriceptive circuits: cellular requirements and mechanisms
Active Grant Awarded
- Award ID
- R21AR088220
- Recipient
-
Trustees Of Indiana University UEI YH86RTW2YVJ4
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $370,494
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 10% complete
- Place of performance
- Bloomington, IN 47405, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Grant R21AR088220 to Trustees of Indiana University, doing business as Indiana University, with $370,494 obligated on September 9, 2026, under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research. The award funds research on cannabinoid receptor 2 (CB2) modulation of pruriceptive circuits, with Specific Aim 1 identifying the cell types required for CB2-mediated itch. Preliminary data show enhanced scratching in global CB2 mice across atopic dermatitis (MC903), allergic contact dermatitis (oxazolone), and acute pruritogen (compound 48/80) models. The project hypothesizes that each itch modality is mediated by one, or at most two, of four candidate cell populations: sensory neurons, keratinocytes, mast cells, and Langerhans cells. The work seeks to define the peripheral sites and mechanisms of CB2 action to support development of topical or peripherally restricted CB2 therapeutics. Work is performed in Bloomington, Indiana 47405, and the ultimate completion date is August 31, 2028.
Description
- Abstract
- Itch (PRURITUS) is not merely an unpleasant sensation - in its chronic form, IT drives sleep loss, anxiety and depression, elicits secondary infection from scratching, and imposes substantial quality-of-life and economic burdens. Despite progress, current anti-itch therapies (e.g., antihistamines, JAK inhibitors, IL-4/13/31 blockers) often only provide partial relief, require close monitoring, and/or are costly, underscoring the need for new, peripherally (i.e., to reduce systemic effects, if possible) targeted strategies. Cannabinoid compounds show anti-inflammatory, anti-proliferative, and anti-pruritic effects in skin. Cannabinoid receptor 2 (CB2), a non-psychoactive G protein-coupled receptor, is expressed in multiple cutaneous compartments and is a promising antipruritic target: preclinical studies suggest CB2 activation reduces itch, several CB2 ligands appear safe in humans, and CB2 has been implicated in inflammatory skin diseases characterized by chronic itch (e.g., psoriasis, atopic dermatitis). However, the peripheral site(S) and mechanism(S) of CB2'S action in keratinocytes, resident immune cells (e.g., mast cells, langerhans cells), and/or sensory neurons, remain undefined, limiting rational development of topical or peripherally restricted CB2 therapeutics. Our preliminary data show enhanced scratching in global CB2−/− mice across several experimental itch models including atopic dermatitis (MC903), allergic contact dermatitis (OXAZOLONE), and acute pruritogen (compound 48/80) paradigms, motivating US to determine the cell population(S) expressing CB2 receptors involved in modulating itch responses. We posit that for each itch modality, CB2'S antipruritic effect is mediated predominantly by one, at most two, cell populations among sensory neurons, keratinocytes, mast cells and langerhans cells. Specific aim 1. Identify the cell type(S) required for CB2-mediated itch suppression using global and cell- specific conditional CB2 knockouts (CKOS) (keratinocyte, sensory neuron, mast cell, and langerhans cell) across histaminergic and non-histaminergic itch modalities, by measuring behavior (scratching/alloknesis ('itch hypersensitivity')) and tissue reaction (ear thickness), followed by pharmacological confirmation. Specific aim 2. For relevant itch modality/CKO pairs identified in aim 1, perform focused molecular and histologic analyses to define modality-specific mechanisms. Specific aim 3. Confirm CB2 presence and cellular localization in mouse (MC903-EXPOSED) and human atopic dermatitis skin biopsies (CO-staining with cellular markers and CNR2 transcript quantification). The expected outcome of these studies is a definitive map of where CB2 acts to suppress itch for each modality tested, supported by molecular and histologic correlates and human tissue CNR2 localization. These findings will focus subsequent mechanistic studies and guide the rational development of topical or peripherally restricted CB2 therapies for itch.
Quick answers
Who received award R21AR088220?
R21AR088220 was awarded to Trustees Of Indiana University by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.
How much is award R21AR088220 worth?
$370,494 has been obligated on R21AR088220.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award